Xinlitai announced that the marketing application for sacubatran alisartan amlodipine tablets independently developed by the company has been accepted by the State Drug Administration and is intended to be used to treat essential hypertension. This product is a fixed combination of ARNI and CCB. No similar product has been approved for marketing in the world. If approved, it will enrich the company's high blood pressure product line.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.